IP Library › Granted Patent US 10,429,385
Granted Patent B2
US 10,429,385 · App. 15/629,705 · Granted Oct 1, 2019

Treating conditions associated with sepsis

Inventors: Ola Winqvist (Uppsala, SE); Graham Cotton (Edinburgh, GB)
Assignee: TLA TARGETED IMMUNOTHERAPIES AB
G01N33/566A61M1/3618A61M1/3679G01N33/56972G01N2333/70596G01N2333/7158G01N2800/065
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,429,385
App. No.
15/629,705
Granted
Oct 1, 2019
Kind
B2
Abstract

A method for treating sepsis and/or respiratory distress syndrome (RDS) comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR5, CXCR1, CXCR2, and/or CCR2 immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally CCR5, CXCR1, CXCR2, and/or CCR2 expressing cells from the peripheral blood of the patient or subject. Various companion therapeutic methods and useful binding reagents are also described.

Claims (8)

1. A method for treating sepsis in a subject in need thereof, which comprises applying peripheral blood from the subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine CXCR1 receptor immobilized directly or indirectly on the support, whereby one or more cells expressing chemokine receptor CXCR1 are removed from the peripheral blood of the subject, wherein the applied blood is recirculated back into the systemic circulation of the subject, and whereby the sepsis is treated.

2. The method of claim 1 , wherein the sepsis is a systemic inflammation syndrome or causes multiple organ dysfunction syndrome.

3. The method of claim 1 , wherein the binding reagent is an agonist or an antagonist of CXCR1.

4. The method of claim 1 , wherein the binding reagent is an antibody or a chemokine.

5. The method of claim 4 , wherein the chemokine is selected from CXCL6, CXCL8.

6. The method of claim 1 , wherein the one or more cells are monocytes, macrophages, or neutrophils.

7. The method of claim 1 , wherein the subject has increased levels of expression of CXCR1 as compared to a subject that does not have sepsis.

8. The method of claim 1 , wherein 20-50% of the subject's blood is applied to the column in a single treatment.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2017
From: WINQVIST, OLA; COTTON, GRAHAM
To: TLA TARGETED IMMUNOTHERAPIES AB
Reel/Frame 044138/0783 →
Continuity (26)
Division 14105628 · Dec 13, 2013
Continuation In Part PCTGB2012051357 · Jun 13, 2012
Continuation In Part PCTGB2012051349 · Jun 13, 2012
Continuation In Part PCTGB2012051348 · Jun 13, 2012
Continuation In Part PCTGB2012051351 · Jun 13, 2012
Continuation In Part PCTGB2012051350 · Jun 13, 2012
Continuation In Part PCTGB2012051355 · Jun 13, 2012
Continuation In Part PCTGB2012051345 · Jun 13, 2012
Continuation In Part PCTGB2012051352 · Jun 13, 2012
Continuation In Part PCTGB2012051346 · Jun 13, 2012
Continuation In Part PCTGB2012051353 · Jun 13, 2012
Continuation In Part PCTGB2012051356 · Jun 13, 2012
Continuation In Part PCTGB2012051354 · Jun 13, 2012
Provisional Application 61496442 · Jun 13, 2011
Provisional Application 61496167 · Jun 13, 2011
Provisional Application 61496288 · Jun 13, 2011
Provisional Application 61496242 · Jun 13, 2011
Provisional Application 61496209 · Jun 13, 2011
Provisional Application 61496195 · Jun 13, 2011
Provisional Application 61496228 · Jun 13, 2011
Provisional Application 61496264 · Jun 13, 2011
Provisional Application 61496184 · Jun 13, 2011
Provisional Application 61496329 · Jun 13, 2011
Provisional Application 61496377 · Jun 13, 2011
Provisional Application 61496352 · Jun 13, 2011
Related Publication 20180038859A1 · Feb 8, 2018